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INTRODUCTION 
In view of Clinically relevant thyroid dysfunction is not uncommon 
during amiodarone  therapy in previous studies and requires careful diagnosis 
and treatment,it was decided to conduct the cross sectional study of thyroid 
dysfunction  among the patients undergoing Amiodarone therapy in the 
chengalpattu  medical college and hospital. 
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AIMS AND OBJECTIVES 
1. To find out the prevalence of Thyroid dysfunction among patient 
undergoing amiodarone therapy 
 
2. To find out the associated risk factors with Thyroid dysfunction among 
patient undergoing Amiodarone therapy  
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REVIEW OF LITERATURE 
AMIODARONE 
Amiodarone  is the potent anti-arrythmic agent.  It is used in a variety of 
cardiac condition  ranging from atrial fibrillation, supra ventricular  tachycardia 
to  Wolf Parkinson White syndrome and ventricular  tachy arrythmias.  When 
compared to other class of anti-arrhythmic drug, amiodarone is unique in 
nature, it appears to be very much useful in patients with significant left 
ventricular dysfunction, the reason being, it does not affect the ejection fraction 
much.  Also its pro-arrhy thmogenic effect when compared to other class of 
Anti arrhythmic is comparatively low.  Hence  we can conclude its use is 
relatively safe in a wide variety of Patient.   
    The structural  property of Amiodarone is very much similar to that 
endogenous thyroid Hormones.  It is chemically a Benzo furanic derivative.  Its 
structural  formula is  almost similar to that of T4.  It contains large amount of 
Iodine  by Nature.  Approximately 37%  Weight of Amiodarone is by Iodine 
weight13.  Usually the maintenance  Dose –daily ranged from 200-600 mg  per 
day and this calculates to amount 7-21 mg lodide are available each day.  This 
results in enormous rise in the urinary iodide excretion and serum lodide  as 
well. 
      Actually the daily Iodide requirement for an average Men or Women 
comes  around 150-200 mcg and if we consider the previous calculation there is 
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50-100 fold excess of Iodide added daily.  In the human body, the Amiodarone is 
distributed  in several tissues starting from liver, adipose tissue, lung and kidney, 
heart, skeletal muscle , thyroid and Brain and after distribution it is slowly 
released from there as well15 
      Amiodarone is slowly cleared from the body in such a way that its 
elimination half life around 50 days (+/-) 23 days15 
      Metabolism of Amiodarone involved three different pathways  and the 
significant  among them would be Dealkylation and 75% eliminated by Bile and 
feces. 
Side effect of Amiodarone therapy: 
     There are various complication of Amiodarone therapy in the body.  These 
include the following... 
1. Corneal microdeposits  
2.  Anorexia, Nausea 
3. Greyish discoloration 
4. Liver function test - Abnormalities 
5. Thyroid dysfuntion        
         hypothyroidism/ hyper thyroidism 
6. Ataxia, tremors, peripheral Neuropathy 
7. Pulmonary fibrosis 
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8. Epididymitis 
9. Conduction abnormalities 
a) Heart block 
b) Sinus bradycardia 
             10. Gynaecomastia  
                                         * Toxic hepatitis is rare.  
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AMIODARONE & THYROID 
           Thyroid hormone is secreted from thyroid gland. These hormones are 
atmost Importance not only for regular function of almost all body organs and 
also for In vitro development of fetus in particular central nervous system. 
     Thyroid hormonogenesis requires appropriate supply of iodide is  crucial  
. Initial step involves  entry of Iodine into the thyrocyte,  the next step involves  
oxidation of Iodide.  Further step involves organification  process by which 
Iodine is attached to tyrosine  residue of thyroglobulin  molecule  at the apical 
membrane of thyrocyte .  Later coupling  reaction takes place, in which 
monoiodo thyronine  attached  with another monoiodo thyronine to form DIT, 
like which Tri iodo (T3) and tetra iodo  thyronine (T4) is  synthesized.  These 
are stored in in the follicle and process of pinocytosis  Thyroid hormone is 
cleaved  from thyroglobulin  and secreted into the circulation.  Thus in the 
circulation, T3 , T4 , rT3 are secreted from thyroid gland. 
      Thyroid gland is the only source of T4 incontrast to that  80% of  T3 
generated by Deiodination of T4 in the Peripheral tissue (predominantly) liver. 
T3 is the biologically active form but present in lower concentration in the 
blood. 
      Thyroid stimulating hormone (TSH) is the hormone, secreted from the 
pituitary in response to various stimuli.  In turn, TSH, stimulate the thyroid 
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gland hormonogenesis and secretion.  As a feedback control, the circulating T4 
and T3 in turn inhibit TSH to maintain its concentration within  normal limit. 
      Inside the tissue T4 enter and converted to T3 by deiodidinase  enzyme 
activity and T3 acts at cellular Nuclear receptor.  This further change the 
cellular transcription and translational and ultimately  protein synthesis and  
thus celluar function. 
Thyroid  dysfunction:  
      Thyroid dysfunction is broadly divided into Hypothyroidism and 
Hyperthyroidism.  Further more it is Subdivided into Subclinical 
hypothyroidism and Subclinical hyperthyroidism. 
Name of the 
condition 
 
TSH 
 
FT4 
 
FT3 
Hypothyroidism Elevated Decreased Normal/Decreased 
Subclinical 
hypothyroidism 
Elevated Normal Normal 
Thyrotoxicosis Decreased Elevated Elevated/high 
normal 
Subclinical 
thyrotoxicosis 
Decreased Normal Normal 
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Amiodarone And Thyroid 
(A) Serum T4 and T3 
   Amiodarone inhibits  Type I 5’ deiodinase18-20  which removes  an atom 
of iodine from the outer ring of T4 to synthesis T3 in the peripheral tissues18-20 
,especially  liver .This result is Increased serum T4 concentration and  decresed 
serum T3 concentration9-12  
 
       Amiodarone also inhibits at the cellular entry in preventing  the thyroid 
hormone entry inside the cell22  this mechanism also helps to understand the rise 
is T4 concentration in these subjects. 
     
  Thus we can understand that amiodarone does not affect the pharmaco 
distribution of T3 or its removal from plasma but its effect on T3 ( via) different 
mechanism . we can conclude that serum T4  concentration will be at the upper 
limit of normal range . some times it may be rised slightly. This rise is initially 
40% of pre treatment value , Used within 2months of amiodarone therapy and 
then reduce to upper limit of normal range. 
       The serum T4 concentration among patients on moderated dosage of 
oral amiodarone like 200 mg/day is usually towards the upper limit of reference 
range. With higher daily dosage of amiodarone the T4 concentration will also 
be elevated slightly above the reference range .  
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   Serum  T3 concentration initially fall during amiodarone therapy and 
returns back for lower reference range but some times will be below normal . 
Free T4 and Free T3 : 
        Thyroid binding globulin level will not be influenced by amiodarone 
therapy and hence FT4, FT3 will be always parallel that of total T4 and total 
T3. 
TSH LEVEL : 
  Amiodarone enters the pituitary gland and inhibits intracellular type 
25’deiodinase activity. This results in the reduced 5’ deiodination of T4 to T3 
and intra pituitary T3 levels fall. As a result TSH  levels will start rising in the 
serum. This rise is usually transient in nature as the FT4 rises and over come 
the less FT3 production. This rise In TSH will not cross usually beyond the 20 
mu/l level. 
    
Another hypothesis is desethylamiodarone (DEA) which is the metabolite 
of amiodarone binds to the intra pituitary T3 receptor which act like T3 
ANTAGONIST .  
On the other hand , suppression of TSH to lower level of reference range 
or even undetectable during treatment of amiodarone in patient which reflect 
subclinical episode of amiodarone induced destructive thyroiditis and 
thyrotoxicosis.  
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AMIODARONE INDUCED THYROTOXICOSIS 
 
 It is otherwise labeled as AIT or thyrotoxicosis   
 Much more common in male67-71 
 Frequently occur in iodine deficient geographical condition62-64 
 Studies failed to prove association between incidence of thyrotoxicosis 
and dosage of amiodarone44 
 Usually acute in onset69. 
 May occur after several months even if drug is discontinued. 
 Remissions are spontaneous in nature. 
 Amiodarone has antiadrenergic property and so the usual clinical 
manifestation of thyrotoxicosis are absent and are detectable via 
laboratory parameters. 
 
     In general arrhythmias in particular, atrial arrhythmia  recurrent in nature 
should arouse the  onset of thyrotoxicosis among the patients under going 
chronic amiodarone therapy. 
 The  pathogenesis of amiodarone induced thyrotoxicosis is complex and 
incompletely studied and only few studies completely analysed it in detail. 
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Excess thyroid hormone synthesis induced by the amiodarone iodine load 
is the main hypothesis. level of iodine inside the thyroid tissue is high and it has 
been studied by the x-ray flourescence and concluded iodine content is 
markedly rised among the amiodarone patients developed thyrotoxicosis 
,irrespective of the presence of intrinsic abnormality in the thyroid gland if any75 
It was found that iodine organification step is not affected in amiodarone 
induced thyrotoxocosis as evident by negative perchlorate discharge test76,77 
Further more it was found that iodine content of thyroid tissue becomes 
normal after the patient becomes Euthyroid while recovering from  Amiodarone 
induced thyrotoxicosis69  when the patient already having thyroid disorder ( as 
latent Grave’s disease) and coming from geographical area of iodine deficient 
and this subgroup population when undergone excess iodine load as amiodarone 
treatment will usually associated with excessive thyroid hormone synthesis. It’s 
also confirmed by the study of RAIU which showed elevated RAIU among 
these subgroup and also assay of serum IL – 6 concentration which is a 
surrogate marker of thyroid destructive process is usually normal stating that 
there is no active destructive process among this subgroup. This is Type -1 AIT 
occurs because of excessive hormonogenesis and this patients are not associated 
with TRab79 
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  The other subgroup population  develop hyperthyroidism among 
amiodarone  therapy who have no abnormality in thyroid gland detected on 
clinical examination or ultrasonographically, usually due to subacute thyroid 
destructive process occurring within thyroid gland.The pathological 
examination of thyroid gland showed there is gland damage with follicular cell 
swelling,cytoplasmic vacuolization and onset of fibrosis. 
 It is proved by experimental study that RAIU activity very low and 
serum IL -6 concentration are markedly elevated78  and further proved by the 
absence of vascularity observed in colour flow Doppler sonography (CFDS 
pattern). 
If the destructive process is in progress the patient will land up in 
hypothyroidism in future89. 
 
Types of AIT  : 
condition Type I Type II 
1. Goiter/prior Thyro 
Auto Ab 
 
Often present 
 
Usually absent 
2. RAIU Normal /increased Low/decreased 
3. Serum IL-6  Normal / slightly raised Highly elevated 
4. CFDS pattern I-III 0 
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5. Response to 
Thionamide 
 
+ 
 
- 
6. Perchlorate 
response 
 
+ 
 
- 
7. Response to 
glucocorticoids 
 
- 
 
Yes (+) 
8. Subsequent 
Hypothyroidism 
 
- 
 
+/- 
 
      In conclusion amiodarone induced thyrotoxicosis  exist in two major 
form . Type 1 Amiodarone induced thyrotoxicosis usually occurs  in a previous 
abnormal thyroid gland and is because of excessive hormonogenesis induced by 
excessive iodine exposure. 
  Type-2  Amiodarone induced Thyrotoxicosis usually occurs due to the 
destruction of thyroid gland and release of preformed thyroid hormones from the 
storage. Mixed forms may exist in reality. Still as a clinician, we should try to 
identify the forms if possible as both are important in the treatment decision. 
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DIAGNOSIS OF AMIODARONE  INDUCED THYROTOXICOSIS : 
Clinical  features 
 Usually not evident as amiodarone has anti- adrenergic effect  
 Consider the possiblity if a patient develops recurrent arrhythmia,  
worsening angina who already taking therapy for longer time. 
 
Biochemical parameters : 
S.No. Condition TSH FT4 FT3 
1. Subclinical 
thyrotoxicosis 
0.03-0.35 High Normal/ 
raised 
Low normal 
2. Thyrotoxicosis < 0.03 Raised/ high 
normal 
Raised/ 
normal 
 
In conditions like sick euthyroid syndrome, a non-thyroidal illness, will 
mimick subclinical thyrotoxicosis but further investigation with serum sex 
hormone binding globulin or serum ferritin ,both are increased , indicating a 
marker of Increased intracellular FT3. 
But if those above investigations are not feasible by an investigator then 
we can repeat the serum TSH ,FT4,FT3 after 6 weeks. 
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TREATMENT OF AMIODARONE INDUCED THYROTOXICOSIS: 
a) Management of Throtoxicosis when Amiodarone      can be stopped:                                                             
       If amiodarone started for simple arrhythmia , which is not life 
threatening, then it can be replaced by another class of anti-arrythmic 
therapy. 
 
Withdrawal of amiodarone needs monitoring : 
i) Worsening of thyrotoxic symptoms should be anticipated as 
amiodarone drug and its metabolite have Anti-adrenergic property 
and its withdrawal have rebound phenomenon. () 
ii) Patients with Type I thyrotoxicosis should be managed as 
follows – 
1) Withdrawal of amiodarone 
2) Thiourea derivatives , carbimazole to block the excessive 
hormone synthesis .  High doses of carbimazole 40-60 mg daily 
in divided doses should be given. 
3)  Propylthiouracil : usually started at the dose of 100-150 mg 
Q6th hourly , is also claimed to be very useful as it inhibits 
peripheral 5” deiodinase activity . 
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4) Potassium perchlorate :mechanism of action appears to block 
the Iodide uptake and results in reduced intrathyroidal iodine 
content. Usually started at the dosage – 0.5 g every 12th hourly. 
5)  General considerations :  
  All anti thyroid drugs need to continue for 3-6 months 
 Watch for development of thyrotoxicosis ,as it has been 
documented that these patients are still hyperthyroid 
upto 6-9 month even after withdrawal of drug. 
 In patients with Thyrotoxicosis type II , with No 
symptoms of hyperthyroidism , may be the candidate for 
stopping amiodarone therapy. 
 Role of steroid in Type II thyrotoxicosis has been 
studied in detail and it should be considered in all 
patients with symptoms of thyrotoxicosis  or worsening 
of arrhythmia. 
 Oral prednisolone is the preferred drug , started at 40-
60mg daily is used and tapered gradually over 3-6 
months. 
 Usually the recovery will be faster by the steroids 
 Anti-thyroid drugs or Radio Iodine treatment are not 
effective in type II thyrotoxicosis. 
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 Mixed form of thyrotoxicosis also been reported in 
patients undergoing Amiodarone therapy. These patients 
are better referred to endocrinologist opinion at the 
earliest.   
 
b) Management of Thyrotoxicosis when Amiodarone cannot be stopped: 
Amiodarone cannot be stopped particularly because of following reasons: 
i) Withdrawal may aggravate thyrotoxic symptoms 
ii) Worsen the cardiac status of the patient 
iii) Other modalities of treatment like ablation therapy, implantable 
defibrillator therapies may not be available or affordable by the 
patient. 
iv) Alternative class of Anti-arrythmic have been failed previously 
before the initiation of amiodarone. 
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 General concensus of treatment when Amiodarone cannot be stopped: 
1) Continuation of amiodarone 
2) Initiate Anti-thyroid drugs for Thyrotoxicosis 
3) Radioactive Iodine may be useful 
4) Maintain TSH concentration to recover to normal level 
5) Surgical management options like Subtotal thyroidectomy or 
Near total thyroidectomy may be considered. 
6) Plasmapheresis: may be useful in severe thyrotoxicosis , tried 
in various studies and found successful .   
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AMIODARONE INDUCED HYPOTHYROIDISM 
a. Epidemiological studies revealed that Amiodarone 
Induced hypoythroidism is more common than 
Amiodarone induced thyrotoxicosis in Iodine sufficient 
areas62. 
b.  In countries with low or intermediate iodine intake , the 
incidence of Amiodarone induced hypothyroidism is as 
low as 6% 62. 
c. Elderly aged patient or female patients are higher risk in 
developing Amiodarone induced hypothyroidism. 
d. Dosage of Amiodarone – whether daily or cumulative is 
not a risk factor for the development of hypothyroidism in 
contrast to Amiodarone induced thyrotoxicosis64. 
e. Presence of Autoimmune Thyroid disorder Is the 
predominant risk factor for the development of 
Amiodarone induced Hypothyroidism. 
f. Female sex and presence of Autoimmune thyroid disease 
as evidenced by Anti-thyroid peroxidase antibodies or 
Anti-thyroglobulin antibodies constitute relative risk of 
13.5% for the development of Hypothyroidism25,44,62.   
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 Pathogenesis : 
Those patients who developing hypothyroidism are unable to escape from 
the Acute wolff-chaikoff effect after an Iodine load125 and inability to perform 
normal thyroid hormone synthesis. 
It is hypothesized that subtle defect already exist in thyroid hormone 
synthesis in these patients and they are not able to escape from the inhibitory 
effect of Iodine. 
Amiodarone is a potent and persistent inhibitor of TSH-mediated cAMP 
production inside the cell. 
Iodine also induce non-specific change in the thyroid follicle which 
favours the development of Hypothyroidism in Hashimoto’s thyroiditis. 
But incontrast , patients who don’t have Thyroid Auto antibodies and 
who doesn’t have thyroid abnormality will have minimal defect in the Iodine 
organification and thus defect in Thyroid hormone synthesis. These 
Amiodarone induced Hypothyroidism may spontaneously remit120,123,127,128. 
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Clinical features : 
a. Non specific symptoms like Lethargy 
b. May have weight gain, apathy, coarse skin and other 
manifestations.   
 
Diagnosis : 
Condition TSH FT4 FT3 
Hypothyroidism >20 mU/L Normal/ decreased Normal / decreased 
Subclinical 
Hypothyroidism 
>4.3-20 mU/L Normal/increased Normal/increasing 
 
Only lowT3  or FT3 are an unreliable indicator of Hypothyroidism as it 
can occur in Euthyroid patients undergoing Amiodarone therapy. 
 
Treatment   
Options include :  
a. If possible stop Amiodarone treatment.  Many patients recover within 4 
months of withdrawal of amiodarone (). Recovery  is much quicker if 
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coadministerd with potassium perchlorate – dosage regimen 1 g daily for 
5 weeks. 
b. Scientific reasons behind this potassium perchlorate administration and 
faster recovery is, potassium perchlorate will inhibit thyroid iodide 
uptake. As a result, Iodide from the thyroid gland will slowly come out 
and its intrathyroidal concentration falls subsequently, which in turn 
decreases or abolishes the inhibitory effect of iodide on hormone 
synthesis. 
c. Potassium perchlorate causes side effects like Aplastic anemia, Gastro 
intestinal upset, rash, nephrotic syndrome .So it is not useful to 
recommend as universal treatment. 
d. Final option is , continue amiodarone and add levothyroxine (T4); adjust 
the dose based on target TSH value. 
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Treatment of subclinical Hypothroidism : 
a. Combination of moderately raised TSH(>4.3 – 20 mU/L) and high 
Normal or elevated FT4 concentration indicate subclinical 
hypothyroidism. 
 
b. It is recommended to do thyroid auto-antibodies among this subgroup. 
If thyroid auto-antibodies are present start with thyroxine 
replacement. 
 
c. If the patient doesn’t have anti-thyroid antibodies, but have symptoms 
of hypothyroidism, it is worthwile to start Thyroxine Repalcement 
and follow up after 3 months and decide to continue further. 
 
d. If the patient doesn’t have anti-thyroid antibodies and no symptoms of 
hypothyroidism, do frequent follow up. Get Endocrinology opinion 
for further management. 
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                                    MATERIALS AND METHODS 
STUDY SETTING: 
Patients attending cardiology out patient department in Chengalpattu 
Medical College and Hospital , Chengalpattu. 
ETHICAL APPROVAL: 
Institutional ethical committee approval was obtained to conduct the study 
STUDY GROUP: 
Patient with Heart disease on amiodarone therapy.  
STUDY DESIGN  : 
Cross sectional study. 
POPULATION TO BE STUDIED: 200 
DURATION OF STUDY:  6 months ( January 2016 – June 2016 )  
CONSENT  : 
All the patients were given written informed consent 
INCLUSTION CRITERIA: 
All patients with Heart disease on treatment with amiodarone therapy for more 
than 3 months are included in the study.  
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EXCLUSION CRITERIA: 
1. Patient admitted for serious comorbid illness like Acute Myocardial     
infarction, sepsis, surgery,trauma,or any other life threatening illness. 
     2.  Patient on amiodarone treatment for less than 3 months. 
     3.  Patient not given consent for this study. 
 
MATERIALS TO BE USED: 
• Blood samples for Thyroid profile- TSH, FT4,FT3. 
METHOD OF COLLECTION OF DATA: 
 SAMPLE SIZE: 
 200 cases will be studied. 
 
PROTOCOL OF THE STUDY 
For every case selected, detailed clinical history , symptoms and signs of 
Hypothyroidism , details of the drugs taken including Amiodarone dosage, 
duration and other cardiac drugs or any other drugs taken,indication for which 
those drugs prescribed, associated comorbid illnesses like Diabetes Mellitus, 
Systemic Hypertension, Hyperlipidemia, Bronchial Asthma, Chronic Kidney 
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disease, pre existing Thyroid disease, family History of Diabetes Mellitus, 
Hypertension, Thyroid Illness, geographical area from which patient residing, 
Dietary history including Iodine intake and  results of routine investigations like 
Complete Blood count, Electrocardiography, X ray chest, Renal function test, 
Liver Function Test, Urine Routine examination, Blood sugar  will be 
prospectively recorded in the semi-structured proforma. Also  In all cases, 
blood for Thyroid Profile, TSH, FT3,FT4 will be taken by performing 
venipuncture and estimation will be done in Clinical Biochemical 
Laboratory, Biochemical Department at chengalpattu medical college 
hospital, Chengalpattu. 
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The following investigations were done to all patients included in 
the study: 
1.Thyoid Profile  
    TSH, FT3, FT4 
2.Renal Function test 
    Sugar 
    Urea 
    Creatinine 
    Electrolytes 
   3. Liver function test 
   Total bilirubin  
   Direct bilirubin 
   SGOT 
   SGPT 
   Alkaline Phosphatase 
   Total protein and Albumin 
       4. Complete blood count including Total count, differential count, ESR 
5.  Xray chest Posteroanterior view and Electrocardiography. 
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Estimation of Thyroid Hormones 
Thyroid Profile estimation- In co-ordination and technical guidance 
with the Department of biochemistry, TSH, FT4, FT3 were measured by 
using chemiluminesence immune-assay and reports will be analysed by 
comparing with the standard reference value. 
 
 Reference values as Follows : 
FT3  -  1.4 - 4.2       pg/ml 
FT4  - 0.8  -2.0        ng/dl 
TSH  - 0.4 -4.2        microIU/ml 
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STATISTICAL TEST   : 
 Risk Factor analysed with Chi-square test, Test of significance is done 
by P value. 
 Prevalence will be given by Percentage.  
 
CONFLICT OF INTEREST: 
     NONE 
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RESULTS AND DISCUSSION 
 
Population characteristics: 
      We conducted the study for the total number of 200 patients out of 
which 24 number of subjects were aged less than 20 years , 63 subjects 
were 20-40 years age group, 72 subject were 40-60 years age group, 35 
subjects belongs to 60-80 years and 6 subjects were more than 80 years .  
Predominant number of patients belong to 40-60 years comes to around 
36% of the study. Next major subgroup belongs to 20-40 years of age 
which accounts for 31.5% . 
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 Table 1. Age category of the studied population 
 
  
Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid  
LESS THAN 20 
 
24 
 
12.0 
 
12.0 
 
12.0 
20-40YEARS 63 31.5 31.5 43.5 
40-60 YEARS 72 36.0 36.0 79.5 
60-80 YEARS 35 17.5 17.5 97.0 
>80  YEARS 6 3.0 3.0 100.0 
Total 200 100.0 100.0  
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Sex Distribution: 
Among these 200 patients studied , male patients were 108 in number 
(54%) of the study and female subjects were 92 (46% of the study).  Among 
these 108  male subjects, majority of them between 40-60 years (42/108, 
38.9%), and 60-80 years (30/108, 27.8%), whereas more than 80 years accounts 
for 3.7% (4/108) and less than 20 years accounts for 4.6%(5/108). 20-40 years 
male population corresponds to 27 subject (25% of the total male population). 
 
Among the 92 female , 36 subjects belong to the age group 20-40 
years(39.1%), 30 subjects belong to 40-60 years (32.6%), 19 subjects belong to 
less than 20 years of age (20.7%), 5 belong to 60-80 years (5.4%) and 2 subject 
more than 80 years (2.2%). 
 
 Age – sex category was analysed using chi-square test and pearson chi 
square value is 28.88 and degree of freedom is 4 and p value comes around p- 
0.00 (p< 0.05) which is statistically significant. 
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 Table 2. showing Sex of the population  
Sex 
 
 
Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
Valid MALE 108 54.0 54.0 54.0 
FEMAL
E 
92 46.0 46.0 100.0 
Total 200 100.0 100.0  
  
Crosstabs 
 Case Processing Summary 
 Cases 
 Valid Missing Total 
 N Percent N Percent N Percent 
sex * 
AGECAT 
200 100.0% 0 .0% 200 100.0% 
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Table 3. Showing Age Sex Category of the population 
 
SEX * AGECAT Crosstabulation 
   AGECAT 
Total 
   LESS 
THAN 20 
20-40 
YEARS 
40-60 
YEARS 
60-80 
YEARS 
>80  
YEARS 
Sex MALE Count 5 27 42 30 4 108 
% within 
sex 
4.6% 25.0% 38.9% 27.8% 3.7% 100.0% 
FEMALE   Count  19 36 30 5 2 92 
% within 
sex 
20.7% 39.1% 32.6% 5.4% 2.2% 100.0% 
Total Count 24 63 72 35 6 200 
% within 
sex 
12.0% 31.5% 36.0% 17.5% 3.0% 100.0% 
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Chi-Square Tests 
 
Value df 
Asymp. Sig. 
(2-sided) 
Pearson Chi-Square 28.881a 4 .000 
Likelihood Ratio 31.217 4 .000 
Linear-by-Linear 
Association 
25.644 1 .000 
N of Valid Cases 200   
 
 
 
 
 
 
 
 
 
 
 
  
 
 
                           Age sex category 
Salt Intake : 
        Among the 200 patients we enrolled ,93/200 subjects were using Iodised 
salt comes to around 46.5% and 107/200 subjects were using deiodised salt by 
53.5% 
            
 
 
 
 
4.60%
25.00%
20.70%
0%
5%
10%
15%
20%
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35%
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45%
LESS THAN 20 20-40YEARS
– Bar diagram (fig 1.)  
27.80%
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5.40%
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 Table 4 showing Salt intake of the population 
Salt 
 
 
Frequency Percent Valid Percent 
Cumulativ
e Percent 
Valid IODISED 93 46.5 46.5 46.5 
DEIODIS
ED 
107 53.5 53.5 100.0 
Total 200 100.0 100.0  
 
 
 
 
 
 
 
 
50 
 
 
Amiodarone Dosage : 
                Out of 200 subjects studied 200 mg was taken by 141 (70.5%),  
300mg was taken by 46 subjects comes to around 46% and 400 mg by 13 
subjects, comes to around 6.5%. 
 
Table 5. showing Dosage Frequency 
Dosage 
 
 
Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid 200 141 70.5 70.5 70.5 
300 46 23.0 23.0 93.5 
400 13 6.5 6.5 100.0 
Total 200 100.0 100.0  
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Comorbidity    : 
                    Among 200 subjects studied Diabetes mellitus was present 
predominantly as a comorbid illness. 46 subjects were Diabetes Mellitus and 
corresponds to 23%. Hypertensive subjects were 26 corresponds to 13%. Both 
diabetes and hypertensive combined comorbid illness present in 13 subjects and 
this corresponds to 6.5% 
 
                  On the otherhand, No comorbid illness was documented in 115 
subjects comes to around 57.5%. 
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Table 6 showing Comorbidity Frequency 
Comordidity 
 
 
Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
Valid DIABETES 46 23.0 23.0 23.0 
HYPERTENSION 26 13.0 13.0 36.0 
DIABETES& HT 13 6.5 6.5 42.5 
NO MORBIDITY 115 57.5 57.5 100.0 
Total 200 100.0 100.0  
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Thyroid function analysis  : 
     FT3: 
                 Out of 200 population studied, normal FT3 comes to 180 subjects, 
increased in 14 subjects and decreased in 6 subjects which correspond to 90%, 
7%, 3% respectively. 
 
Table 7 Showing FT3 Frequency  
FT3 
  
Frequency Percent 
Valid 
Percent 
Cumulativ
e Percent 
Valid NORMAL 180 90.0 90.0 90.0 
INCREASED 14 7.0 7.0 97.0 
DECREASED 6 3.0 3.0 100.0 
Total 200 100.0 100.0  
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  FT4  : 
                  Out of 200 population studied, normal FT4 found in 168 subjects 
(84%),  in 27 subject increased FT4 ( 13.5%),  decreased in 5 subjects ( 2.5%). 
 
Table 8 showing FT4 Frequency 
FT4 
 
 
Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
Valid NORMAL 168 84.0 84.0 84.0 
INCREASED 27 13.5 13.5 97.5 
DECREASED 5 2.5 2.5 100.0 
Total 200 100.0 100.0  
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  TSH  : 
          Out of 200 subjects studied normal TSH were documented in 144 (72%), 
increased in 26 ( 13%), decreased in 30 subjects (15%). 
 
Table 9 showing TSH frequency 
TSH 
 
 
 
Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid NORMAL 144 72.0 72.0 72.0 
INCREASED 26 13.0 13.0 85.0 
DECREASED 30 15.0 15.0 100.0 
Total 200 100.0 100.0  
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Table 10 showing Prevalence of Thyroid Dysfunction 
OUTCOME 
 
 
Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
Valid SUBCLINICAL 
HYPOTHYRIODISM 
19 9.5 9.5 9.5 
CLINICAL 
HYPOTHYROIDISM 
5 2.5 2.5 12.0 
THYROTOXICOSIS 17 8.5 8.5 20.5 
SUBCLINICAL 
THYROTOXICOSIS 
13 6.5 6.5 27.0 
NORMAL 146 73.0 73.0 100.0 
Total 200 100.0 100.0  
 
Prevalence : 
           Based on the above observation , it was found that subclinical 
hypothyroidism present in 19 subjects (9.5%),  clinical hypothyroidism present 
in 5 subjects (2.5%), thyrotoxicosis present in 17 subjects (8.5%), subclinical 
 thyrotoxicosis present in 13 subje
number (73%). 
 
Fig 2 showing prevalence of thyroid dysfunction
Prevalence from our study as follows:
1. Suclinical Hypothyroidism          9.5%
2. Clinical Hypothyroidism              2.5%
3. Thyrotoxicosis              
4. Subclinical thyrotoxicosis           6.5%
           Overall prevalence of thyroid dysfunction corresponds to 27% among the 
200 population studied.     
9.50%
73%
cts (6.5%) and normal subjects were 146 in 
 
 
 
 
 
                 8.5% 
 
2.50%
8.50%
6.50%
SUBCLINICAL 
HYPOTHYRIODISM
CLINICAL 
HYPOTHYROIDISM
THYROTOXICOSIS
SUBCLINICAL 
THYROTOXICOSIS
NORMAL
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           Overall incidence of Amiodarone induced Thyrotoxicosis ranging from 1 
to 23% and Amiodarone induced Hypothyroidism ranging from 1% to 32% - 
published in various studies11     
Symptom analysis : 
             The following symptoms are present in the patient ; palpitation present 
in 5 subjects (25%), weight loss present in 4 subjects (2%), Dyspnoea were 
present in 9 subjects( 4.5%), lethargy present In 4 subjects (2%), and No 
symptoms in 178 subjects ( 89%). 
             So predominantly No symptoms, and if symptoms present Dyspnoea  is 
the commonest symptom. When analysed with cross table, Dyspnoea present in 
both Hypothyroidism and hyperthyroidism. 2 subjects with hypothyroidism and 
7 subjects with hyperthyroidism were present with Dyspnoea. Palpitation 
present in 5 subjects only with hyperthyroidism (100%). Lethargy in 4 subjects 
only with Hypothyroidism(100%). No symptoms present in 18 subjects with 
hypothyroidism(10.1%) and 14 subjects with Hyperthyroidism(7.9%). with chi-
square test , pearson chi-square value is 1.199E2, with degree of freedom 8, 
with p value corresponds to 0.00(p<0.05) which is statistically significant. 
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Table 11 FREQUENCY OF SYMPTOMS 
clinical sympyoms 
 
 
Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
Valid PALPITATION 5 2.5 2.5 2.5 
WT LOSS 4 2.0 2.0 4.5 
DYSPNOEA 9 4.5 4.5 9.0 
LETHARGY 4 2.0 2.0 11.0 
NORMAL 178 89.0 89.0 100.0 
Total 200 100.0 100.0  
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Table 12 Symptoms cross tab analysis 
CLINICAL SYMPYOMS * HYPOHYPER 
 
Crosstab 
   HYPOHYPER 
Total 
  clinical sympyoms HYPOTHY
ROIDISM 
HYPERTH
YROIDISM NORMAL 
 
PALPITATION Count 0 5 0 5 
% within clinical 
sympyoms 
.0% 100.0% .0% 100.0% 
WT LOSS Count 0 4 0 4 
% within clinical 
sympyoms 
.0% 100.0% .0% 100.0% 
DYSPNOEA Count 2 7 0 9 
% within clinical 
sympyoms 
22.2% 77.8% .0% 100.0% 
LETHARGY Count 4 0 0 4 
% within clinical 
sympyoms 
100.0% .0% .0% 100.0% 
NORMAL Count 18 14 146 178 
% within clinical 
sympyoms 
10.1% 7.9% 82.0% 100.0% 
      Total Count 24 30 146 200 
% within clinical 
sympyoms 
12.0% 15.0% 73.0% 100.0% 
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Chi-Square Tests 
 Value df Asymp. Sig. (2-sided) 
Pearson Chi-Square 1.199E2a 8 .000 
Likelihood Ratio 86.406 8 .000 
Linear-by-Linear 
Association 
24.676 1 .000 
N of Valid Cases 200   
a. 11 cells (73.3%) have expected count less than 5. The minimum expected 
count is .48. 
 
         Hawthorne et al, reported eight case of Amiodarone induced 
hypothyroidism with lethargy , Dry skin, Cold intolerance as the predominant 
symptoms123. In our study , lethargy is the predominant symptom with a 
Amiodarone induced hypothyroidism. 
         Martino E et al(ref) reported worsening tachyarrhythmia or angina is the 
common symptom  in  Amiodarone induced thyroxicosis in his study – 
Amiodarone , a common source of Iodine induced thyrotoxicosis62. 
         Harjai KJ et al11, in the study effects on amiodarone on thyroid function 
and  Iducia souza C et al12, in the study Amodarone induced thyroid 
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dysfunction, reported that mostly Amiodarone induced thyrotoxicosis is 
asymptomatic because of Amiodarone Antiadrenergic property. 
        In our study also out of 30 subjects with hyperthyroidism , 14 subjects 
were Asymptomatic and among symptomatic dyspnoea is common 
presentation which may be angina equivalent. P value corresponds to 0.00 
(p<0.05) which is statistically significant.  
Indication of Amiodarone : 
         Out of 200 subject studied Supraventricular tachycardia accounts for 77 
patient; among 77 subjects 20 developed hyperthyroidism (26%), 9 developed 
hypothyroidism (11.7%), 63 person were dilated cardiomyopathy , out of which 
10 developed hypothyroidism( 15.9%), 9 developed hyperthyroidism (14.3%). 
39 subjects were Atrial fibrillation , amomg which 5 developed Hypothyroidism 
(12.8%), none developed hyperthyroidism.  
          7 subjects were Wolf Parkinson White syndrome , out of which 1 
develped hyperthyroism(14.3%), none developed Hypothyroidism. 
14 subjects were ventricular tachycardia, out of which none developed thyroid 
dysfunction. 
          On chi-square test analysis, pearson chi-square value is 21.4, degree of 
freedom 8, p value corresponds to less than 0.006(p<0.05) which is statistic ally 
significant. 
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Table 13 SHOWING  INDICATION * HYPOHYPER cross tab analysis 
Crosstab 
   HYPOHYPER 
Total 
  INDICATION HYPOTHY
ROIDISM 
HYPERTH
YROIDISM NORMAL 
 SVT Countn 9 20 48 77 
% within 
indication 
11.7% 26.0% 62.3% 100.0% 
DCMP Count 10 9 44 63 
% within 
indication 
15.9% 14.3% 69.8% 100.0% 
AF Count 5 0 34 39 
% within 
indication 
12.8% .0% 87.2% 100.0% 
WPW Count 0 1 6 7 
% within 
indication 
.0% 14.3% 85.7% 100.0% 
VT Count 0 0 14 14 
% within 
indication 
.0% .0% 100.0% 100.0% 
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Total Count 24 30 146 200 
% within 
indication 
12.0% 15.0% 73.0% 100.0% 
 
  
Chi-Square Tests 
 Value df Asymp. Sig. (2-sided) 
Pearson Chi-Square 21.404a 8 .006 
Likelihood Ratio 30.527 8 .000 
Linear-by-Linear Association 8.458 1 .004 
N of Valid Cases 200   
a. 5 cells (33.3%) have expected count less than 5. The minimum expected count 
is .84. 
 
         From our study it can be informed that Amiodarone inferred thyroid 
dysfunction is common among supraventricular tachyarrhythmia when 
compared to ventricular tachyarrthia. 
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Co Morbid Illness Analysis :  
          Among 200 patient studied 24 patients developed hypothyroidism. 
Among these 24 subjects Diabetes mellitus alone present in 7 subjects. Diabetes 
and hypertension present in 3 subjects. No comorbid illness present in 14 
subjects and nobody with hypertension developed Thyroid dysfunction. 
         Among 200 subjects 30 subjects were developed hyperthyroidism. 21 
subjects were have no comorbid illness. 1 had Diabetes mellitus and 
hypertension . 8 subjects had Diabetes Mellitus alone. Patients with 
Hypertension have not developed hyperthyroidism. 
         So Diabetes Mellitus patient will appear to have more Risk factor for 
developing Thyroid dysfunction when compared to Hypertension. Statistical 
analysis shows P value p-0.04 (P<0.05) which is statistically significant. 
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COMORDIDITY * HYPOHYPER 
Table 14 Comorbidity Crosstab Analysis 
  
HYPOHYPER 
Total  COMORDIDITY HYPOTHY
ROIDISM 
HYPERTH
YROIDISM NORMAL 
 DIABETES Count 7 8 31 46 
% within 
comordidity 
15.2% 17.4% 67.4% 
100.0
% 
HYPERTENSION Count 0 0 26 26 
% within 
comordidity 
.0% .0% 100.0% 
100.0
% 
DIABETES& HT Count 3 1 9 13 
% within 
comordidity 
23.1% 7.7% 69.2% 
100.0
% 
NO MORBIDITY Count 14 21 80 115 
% within 
comordidity 
12.2% 18.3% 69.6% 
100.0
% 
     Total Count 24 30 146 200 
% within 
comordidity 
12.0% 15.0% 73.0% 
100.0
% 
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Chi-Square Tests 
 Value df Asymp. Sig. (2-sided) 
Pearson Chi-Square 13.208a 6 .040 
Likelihood Ratio 19.688 6 .003 
Linear-by-Linear Association .244 1 .621 
N of Valid Cases 200   
a. 4 cells (33.3%) have expected count less than 5. The minimum expected count is 
1.56. 
 
 Dosage Analysis : 
           Among 200 population studied 141 subjects were taking 200 mg. among 
141 subjects 138 were normal , 1 developed hyperthyroidism( 0.07%), 2 
dveloped hypothyroidism (14%).  
          Among 200 population studied 46 subjects were taking 300 mg per day 
amiodarone . out of 46 , 7 were normal (15.2%). 20 developed (43.5%) 
hyperthyroidism, 19  developed (41.3 %) hypothyroidism. Among 200 subjects 
studied 13 subjects were taking Amiodarone in the dose 400 mg per day. Out of 
13 1 found to be normal(7.7%). 9 were developed hyperthyroidism (69.2%), 3 
developed hypothyroidism (23.1%). 
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Statistical analysis with chi-square analysis revealed p value is 0.00 (p<0.05) 
which is statistically significant. 
 
DOSAGE * HYPOHYPER 
Table 15 dosage Crosstab analysis 
   HYPOHYPER 
Total 
 
 DOSAGE HYPOTHY
ROIDISM 
HYPERTH
YROIDISM NORMAL 
 200 Count 2 1 138 141 
% within 
dosage 
1.4% .7% 97.9% 100.0% 
300 Count 19 20 7 46 
% within 
dosage 
41.3% 43.5% 15.2% 100.0% 
400 Count 3 9 1 13 
% within 
dosage 
23.1% 69.2% 7.7% 100.0% 
Total Count 24 30 146 200 
% within 
dosage 
12.0% 15.0% 73.0% 100.0% 
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Chi-Square Tests 
 Value df Asymp. Sig. (2-sided) 
Pearson Chi-Square 1.575E2a 4 .000 
Likelihood Ratio 160.818 4 .000 
Linear-by-Linear 
Association 
103.709 1 .000 
N of Valid Cases 200   
a. 2 cells (22.2%) have expected count less than 5. The minimum expected 
count is 1.56. 
 
Duration analysis :  
            Among 200 patient were studied , 4 subjects taking 6 month duration, 2 
subjects taking 8 month duration , 3 subjects taking 10 month duration, 75 
subjects taking 12 month duration, 29 subjects taking 15 month duration , 3 
subjects taking 16  moth duration, 39 subjects were taking 18 month duration, 1 
subject taking 20 month duration, 29 subjects taking 24 months duration. 
            Out of 24 subjects with hypothyroidism predominant patient (10/24) 
were taking 12 month duration therapy. Among 30 subjects with 
hyperthyroidism, 15 patients were taking beyond 18 months duration. 
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          Trip et al44 observed that average duration of therapy before the 
occurrence of Amiodarone induced  thyrotoxicois  was about 3 years with 
probability rising after 18 months. 
 
          Marino et al65 study, prospective analysis showed that Amiodarone 
induced thyrotoxicosis developed after 12 months. 
 
         Wiersinger et al9 and Braverman LE et al78 , studied in different 
periods and observed Amiodarone induced Hypothyroidism Was occurred very 
early on the treatment duration (3month – 12 month duration).  
 
         In our study also amiodaone induced hypothyroidism occurs 
predominantly within 15 months beyond which the prevalence decreases. 
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DURATION  * HYPOHYPER 
Table 16 Duration of Amiodarone Crosstab 
   HYPOHYPER 
Total 
  DURATION HYPOTHYR
OIDISM 
HYPERTH
YROIDISM NORMAL 
 6 Count 1 0 6 7 
% within duration  
14.3% .0% 85.7% 
100.0
% 
8 Count 0 0 2 2 
% within duration  
.0% .0% 100.0% 
100.0
% 
10 Count 0 0 3 3 
% within duration  
.0% .0% 100.0% 
100.0
% 
12 Count 10 8 57 75 
% within duration  
13.3% 10.7% 76.0% 
100.0
% 
14 Count 0 3 9 12 
% within duration  
.0% 25.0% 75.0% 
100.0
% 
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15 Count 7 3 19 29 
% within duration  
24.1% 10.3% 65.5% 
100.0
% 
16 Count 0 1 2 3 
% within duration  
.0% 33.3% 66.7% 
100.0
% 
18 Count 5 8 26 39 
% within duration  
12.8% 20.5% 66.7% 
100.0
% 
20 Count 0 0 1 1 
% within duration  
.0% .0% 100.0% 
100.0
% 
24 Count 1 7 21 29 
% within duration  
3.4% 24.1% 72.4% 
100.0
% 
      Total Count 24 30 146 200 
% within duration  
12.0% 15.0% 73.0% 
100.0
% 
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Chi-Square Tests 
 Value df Asymp. Sig. (2-sided) 
Pearson Chi-Square 16.504a 18 .557 
Likelihood Ratio 20.304 18 .316 
Linear-by-Linear Association .039 1 .844 
N of Valid Cases 200   
a. 21 cells (70.0%) have expected count less than 5. The minimum expected count is 
.12. 
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Sex Analysis : 
          Among 200 subjects studied , 108 subjects were male subjects . out of 
108 male 16 developed hyperthyroidism, 8 developed hypothyroidism, among 
92 female , 16 developed hypothyroidism , 14 developed hyperthyroidism.  
         Out of 24 hypothyroid patients 8 were male, 16 were female which 
appears to be in higher percentage but the value is 0.088 (p <0.05) which is not 
significantly statistically. 
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SEX * HYPOHYPER 
Table 17 Sex and Thyroid dysfunction Crosstab 
   HYPOHYPER 
Total 
   HYPOTHY
ROIDISM 
HYPERTH
YROIDISM NORMAL 
sex MALE Count 8 16 84 108 
% within 
sex 
7.4% 14.8% 77.8% 100.0% 
FEMALE Count 16 14 62 92 
% within 
sex 
17.4% 15.2% 67.4% 100.0% 
Total Count 24 30 146 200 
% within 
sex 
12.0% 15.0% 73.0% 100.0% 
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Chi-Square Tests 
 Value df Asymp. Sig. (2-sided) 
Pearson Chi-Square 4.866a 2 .088 
Likelihood Ratio 4.898 2 .086 
Linear-by-Linear 
Association 
4.292 1 .038 
N of Valid Cases 200   
a. 0 cells (.0%) have expected count less than 5. The minimum expected count is 
11.04. 
 
Salt intake analysis  : 
      Among 200 subjects enrolled , 24 developed hypothyroidism. Out of 24 , 13 
were in deiodised , 11 were in iodised salt intake category . Among 30 subjects 
who developed hyperthyroidism 25 subjects were consuming deiodised salt, 5 
subjects were consuming iodised salt . 
     Statistical analysis in chi-square test showed, pearson chi-square value 
13.0222, degree of freedom is 2 and p value is 0.001 (p<0.05) which is highly 
significant. 
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SALT * HYPOHYPER 
Table 18 showing Iodine and thyroid dysfunction Crosstab 
   HYPOHYPER 
Total 
 SALT  HYPOTHY
ROIDISM 
HYPERTH
YROIDISM NORMAL 
 IODISED Count 11 5 77 93 
% within 
salt 
11.8% 5.4% 82.8% 100.0% 
DEIODISED Count 13 25 69 107 
% within 
salt 
12.1% 23.4% 64.5% 100.0% 
    Total Count 24 30 146 200 
% within 
salt 
12.0% 15.0% 73.0% 100.0% 
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Chi-Square Tests 
 Value df Asymp. Sig. (2-sided) 
Pearson Chi-Square 13.022a 2 .001 
Likelihood Ratio 14.180 2 .001 
Linear-by-Linear Association 3.596 1 .058 
N of Valid Cases 200   
a. 0 cells (.0%) have expected count less than 5. The minimum expected count is 
11.16. 
 
        Martino et al study62, Amiodarone induced thyrotoxicosis appears to 
occur more frequently in area with low iodine intake whereas Amiodarone 
induced Hypothyroidism occur more commonly in iodine significant areas. 
 
       In our study group, Amiodarone induced thyrotoxicosis occurs more 
frequently in deiodised salt intake subjects whereas Amiodarone induced 
hypothyroidism occurs equally but slightly higher in  sufficient Iodine 
consuming individual. 
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Age Analysis : 
         Among 24 subjects developed hypothyroidism, patients were distributed 
uniformly from less than 20 years of age to 80 years of age. Predominant group 
involved is 40-60 years of age, 13 subjects in that age group developed 
hypothyroidism. 
         Among 30 subjects who developed hyperthyroidism, predominantly the 
patient age belong to 20-40 years and 40 -60 years developed hyperthyroidism 
corresponds to 11 subjects and 10 subjects respectively. 
        But the p value corresponds to 0.335 (p> 0.05) which Is statistically 
insignificant. So in our study amiodarone  induced thyroid dysfunction will 
occur in all age group when compared to foreign studies. 
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AGECAT * HYPOHYPER 
Table 19 age and thyroid sysfunction Crosstab 
   HYPOHYPER 
Total 
 AGE  CATEGORY HYPOTHY
ROIDISM 
HYPERTH
YROIDISM NORMAL 
 LESS THAN 
20 
Count 4 4 16 24 
% within 
AGECAT 
16.7% 16.7% 66.7% 100.0% 
20-40YEARS Count 2 11 50 63 
% within 
AGECAT 
3.2% 17.5% 79.4% 100.0% 
40-60 
YEARS 
Count 13 10 49 72 
% within 
AGECAT 
18.1% 13.9% 68.1% 100.0% 
60-80 
YEARS 
Count 5 4 26 35 
% within 
AGECAT 
14.3% 11.4% 74.3% 100.0% 
>80  YEARS Count 0 1 5 6 
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% within 
AGECAT 
.0% 16.7% 83.3% 100.0% 
Total Count 24 30 146 200 
% within 
AGECAT 
12.0% 15.0% 73.0% 100.0% 
 
 
Chi-Square Tests 
 Value df Asymp. Sig. (2-sided) 
Pearson Chi-Square 9.082a 8 .335 
Likelihood Ratio 11.169 8 .192 
Linear-by-Linear 
Association 
.040 1 .841 
N of Valid Cases 200   
a. 6 cells (40.0%) have expected count less than 5. The minimum expected count is 
.72. 
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TSH * HYPOHYPER 
Table 20 TSH Crosstab 
   HYPOHYPER 
Total 
   HYPOTHY
ROIDISM 
HYPERTH
YROIDISM NORMAL 
TSH NORMAL Count 0 0 144 144 
% within 
TSH 
.0% .0% 100.0% 100.0% 
INCREASED Count 24 0 2 26 
% within 
TSH 
92.3% .0% 7.7% 100.0% 
DECREASED Count 0 30 0 30 
% within 
TSH 
.0% 100.0% .0% 100.0% 
Total Count 24 30 146 200 
% within 
TSH 
12.0% 15.0% 73.0% 100.0% 
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Chi-Square Tests 
 Value df Asymp. Sig. (2-sided) 
Pearson Chi-Square 3.821E2a 4 .000 
Likelihood Ratio 293.394 4 .000 
Linear-by-Linear Association 105.883 1 .000 
N of Valid Cases 200   
 
a. 4 cells (44.4%) have expected count less than 5. The minimum expected count is 
3.12. 
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FT4 * HYPOHYPER 
Table 21 FT4 Crosstab 
   HYPOHYPER 
Total 
   HYPOTHY
ROIDISM 
HYPERTH
YROIDISM NORMAL 
fT4 NORMAL Count 19 3 146 168 
% within 
fT4 
11.3% 1.8% 86.9% 100.0% 
INCREASED Count 0 27 0 27 
% within 
fT4 
.0% 100.0% .0% 100.0% 
DECREASED Count 5 0 0 5 
% within 
fT4 
100.0% .0% .0% 100.0% 
Total Count 24 30 146 200 
% within 
fT4 
12.0% 15.0% 73.0% 100.0% 
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Chi-Square Tests 
 Value df Asymp. Sig. (2-sided) 
Pearson Chi-Square 2.137E2a 4 .000 
Likelihood Ratio 159.537 4 .000 
Linear-by-Linear Association 55.002 1 .000 
N of Valid Cases 200   
 
a. 5 cells (55.6%) have expected count less than 5. The minimum expected count 
is .60. 
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FT3 * HYPOHYPER 
Table 22 FT3 Crosstab 
   HYPOHYPER 
Total 
   HYPOTHY
ROIDISM 
HYPERTH
YROIDISM NORMAL 
FT3 NORMAL Count 16 18 146 180 
% within 
fT3 
8.9% 10.0% 81.1% 100.0% 
INCREASED Count 2 12 0 14 
% within 
fT3 
14.3% 85.7% .0% 100.0% 
DECREASED Count 6 0 0 6 
% within 
fT3 
100.0% .0% .0% 100.0% 
Total Count 24 30 146 200 
% within 
fT3 
12.0% 15.0% 73.0% 100.0% 
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Chi-Square Tests 
 Value df Asymp. Sig. (2-sided) 
Pearson Chi-Square 1.070E2a 4 .000 
Likelihood Ratio 74.537 4 .000 
Linear-by-Linear Association 53.621 1 .000 
N of Valid Cases 200   
 
a. 5 cells (55.6%) have expected count less than 5. The minimum expected count is 
.72. 
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Table 23 showing the Mean value of FT3, FT4, TSH among the amiodarone 
patient- with normal thyroid function 
 
 
 
 
 
Descriptives 
 
  
N Mean 
Std. 
Deviation 
Std. 
Error 
95% Confidence 
Interval for Mean 
M
in
im
u
m
 
M
a
x
im
u
m
 
  Lower 
Bound 
Upper 
Bound 
          
FT3      
NORMAL 
146 2.6768 .82909 .06862 2.5412 2.8125 1.30 4.28 
FT4   
NORMAL 
146 1.410 .4397 .0364 1.338 1.482 .8 2.2 
TSH     
NORMAL 
146 2.4856 1.15923 .09594 2.2960 2.6752 .40 4.61 
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CONCLUSION 
Amiodarone induced thyroid dysfunction is common in our study group 
Prevalence from our study as follows: 
1. Subclinical Hypothyroidism           9.5% 
2. Clinical Hypothyroidism               2.5% 
3. Thyrotoxicosis                               8.5% 
4. Subclinical thyrotoxicosis             6.5% 
Overall prevalence of thyroid dysfunction corresponds to 27% among the 200 
population studied.     
1. Amiodarone induced thyrotoxicosis occurs predominantly in low 
iodine intake individual 
2. Diabetes Mellitus when coexist with Amiodarone treated patients 
Thyroid dysfunction is more common 
3. Thyroid dysfunction is common among supraventricular 
tacharrhythmia with amiodarone compared to ventricular 
tachyarrhythmia with amiodarone. 
4. Dyspnoea is a common clinical symptom among thyroid dysfunction 
patient but asymptomatic patients are even higher suggesting to do 
screening thyroid function routinely in all individual. 
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5. As Amiodarone dosage increases the chance of thyroid dysfunction 
increases. 
6. Duration of Amiodarone therapy in our study includes 24 months and 
hypothyroidism occurs  predominantly within 15 months and 
hyperthyroidism occurs predominantly after 15 months. 
7. Hypothyroidism is more common in female sex, whereas 
hyperthyroidism occurs almost equally in both sexes in our study. 
8. Age is not a significant risk factor in the development of thyroid 
dysfunction although predominant subjects with hypothyroidism 
occurs in 40-60 years and predominant subjects with hyperthyroidism 
ocuurs in 20-60 years. 
9. It is recommended to do thyroid function test in patients undergoing 
amiodarone therapy more than 3 months duration and follow up them 
if warrented. 
10. In our study all the patient with hypothyroidism were started on 
levothyroxine treatment and all hyperthyroidism were started on 
antithyroid drugs and all of them referred to get Endocrinology 
opinion for further management.  
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           Thyroid dysfunction is very common in our part of country; since our 
geographical area is mixed with iodine deficient and iodine sufficient 
population, it is very important to do thyroid function test among patient 
undergoing chronic Amiodarone Therapy; still larger studies are needed in this 
area as it is first study in our population ,to become it generalised. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
92 
 
                                                         PROFORMA 
1.NAME                                       : 
2.AGE                                           : 
3.SEX                                            : 
4.OCCUPATION                          : 
5.ADDRESS                                 : 
6.DIAGNOSIS                              : 
7.DURATION OF AMIODARONE THERAPY : 
8.DOSAGE OF AMIODARONE                          : 
9. DETAILS OF OTHER DRUGS                        : 
10. COMPLAINTS IF ANY                                  : 
11.PRE-EXISTING ILLNESS                               :  THYROID/DIABETES        
    MELLITUS/HYPERTENSION/ ANY OTHER ILLNESS. 
12.PERSONAL HABITS                             :  SMOKING / ALCOHOL / 
TOBACCO CHEWING/ ANY OTHER 
13.DIETARY DETAILS                                   : IODINISED SALT/ ANY         
    DIET AFFECTING THYROID  FUNCTION ETC.,  
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14. OTHER RELEVANT DETAILS                 : 
15.THYROID PROFILE  RESULT                  : 
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and any further research that may be conducted in relation to it, even if withdraw from 
the study, I understand that my identity will not be revealed in any information released 
to third parties or published, unless as required under the law. I agree not to restrict the 
use of any data or results that arise from the study. 
I agree to take part in the above study and to comply with the instructions given during 
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unexpected or unusual symptoms. 
I hereby give consent to participate in this study. 
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MASTER CHART 
sno age sex salt  duration months dosage comordidity indication clinical sympyoms FT3 fT3 fT4 fT4 TSH TSH OUTCOME 
1 54 M I 12 MON 200 DM SVT NIL 1.83 N 1.90 N 3.23 N NORMAL 
2 60 M D 18 MON 200 HT DCMP NIL 3.99 N 1.97 N 3.80 N NORMAL 
3 45 F D 12 MON 200 NIL SVT NIL 1.67 N 0.86 N 3.78 N NORMAL 
4 35 F D 18 MON 300 NIL SVT NIL 4.20 N 2.10 N 9.29 I HYPO-SUB 
5 87 F D 15 MON 300 DM SVT PALPITATION 2.30 N 4.50 I 0.02 D THYROTOXICOSIS 
6 63 F I 15 MON 400 DM DCMP NIL 3.99 N 1.99 N 8.59 I HYPO-SUB 
7 50 F D 12 MON 200 NIL AF NIL 2.40 N 1.40 N 3.24 N NORMAL 
8 53 F D 12 MON 300 NIL AF NIL 3.90 N 1.80 N 6.29 I HYPO-SUB 
9 50 F I 14 MON 200 HT DCMP NIL 1.50 N 1.99 N 3.23 N NORMAL 
10 50 M I 12 MON 200 DM SVT NIL 4.10 N 1.90 N 3.67 N NORMAL 
11 50 F I 15 MON 300 NIL DCMP NIL 1.42 N 2.00 N 15.75 I HYPO-SUB 
12 43 M D 24 MON 200 DM DCMP NIL 1.50 N 1.90 N 3.80 N NORMAL 
13 45 F I 12 MON 300 DM DCMP DYSPNOEA 0.70 D 0.60 D 28.76 I HYPO-CLI 
14 38 M I 14 MON 300 NIL SVT NIL 3.00 N 2.90 I 0.20 D HYPER 
15 30 M I 6 MON 200 DM DCMP NIL 3.66 N 2.00 N 1.50 N NORMAL 
16 28 M D 12 MON 200 NIL SVT NIL 1.90 N 1.20 N 5.47 I HYPO-SUB 
17 65 M I 12 MON 300 NIL SVT NIL 4.60 I 1.90 N 5.46 I HYPO-SUB 
18 72 M D 14 MON 300 NIL SVT DYSPNOEA 7.92 I 5.90 I 0.01 D THYROTOXICOSIS 
19 45 M I 10 MON   200 NIL AF NIL 4.00 N 1.90 N 2.19 N NORMAL 
20 45 M D 14 MON 200 NIL SVT NIL 2.04 N 1.60 N 2.31 N NORMAL 
21 65 M I 12 MON 300 DM DCMP NIL 0.57 D 1.96 N 8.31 I HYPO-SUB 
22 66 M D 18 MON 400 NIL DCMP NIL 4.00 N 7.30 I 0.30 D SUBCLINI THYROTOX 
23 24 M I 12 MON 200 NIL SVT NIL 3.08 N 1.20 N 1.16 N NORMAL 
24 28 M D 12 MON 200 NIL AF NIL 1.76 N 1.30 N 3.24 N NORMAL 
25 45 M D 24 MON 200 DM DCMP NIL 1.80 N 1.50 N 4.21 N NORMAL 
26 62 M I 18 MON 300 DM DCMP DYSPNOEA 0.40 D 0.00 D 23.83 I HYPO-CLI 
27 18 M I 18 MON 300 NIL WPW DYSPNOEA 7.24 I 9.00 I 0.02 D SUBCLINI THYROTOX 
28 48 M D 16 MON 200 NIL WPW NIL 2.60 N 1.00 N 0.89 N NORMAL 
29 57 M I 6 MON 200 DM DCMP LETHARGY 1.37 N 2.10 N 12.82 I HYPO-SUB 
30 67 M I 24 MON 200 DM DCMP NIL 2.30 N 1.90 N 1.74 N NORMAL 
31 32 M I 18 MON 300 NIL SVT palpitation 7.38 I 6.90 I 0.01 D THYROTOXICOSIS 
32 58 M I 12 MON 200 NIL DCMP NIL 2.90 N 1.20 N 2.65 N NORMAL 
33 61 M D 12 MON 200 NIL DCMP NIL 2.67 N 1.55 N 3.42 N NORMAL 
34 60 F D 18 MON 300 NIL SVT NIL 4.56 N 1.99 N 7.65 I HYPO-SUB 
35 25 F D 18 MON 300 NIL SVT palpitation 9.39 I 9.40 I 0.07 D SUBCLINI THYROTOX 
36 66 F I 18 MON 200 HT DCMP NIL 3.30 N 2.20 N 3.90 N NORMAL 
37 45 F D 12 MON 200 HT AF NIL 2.98 N 1.22 N 0.74 N NORMAL 
38 60 F I 24 MON 200 HT WPW NIL 3.13 N 1.76 N 0.89 N NORMAL 
39 38 F D 24 MON 400 NIL SVT NIL 1.43 N 7.40 I 0.04 D SUBCLINI THYROTOX 
40 20 F I 12 MON 200 NIL SVT NIL 2.89 N 1.23 N 2.30 N NORMAL 
41 60 F D 15 MON  300 DM,HT DCMP LETHARGY 0.80 D 0.00 D 21.36 I HYPO-CLI 
42 32 F D 12 MON 200 NIL SVT NIL 3.80 N 0.95 N 1.91 N NORMAL 
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43 39 F I 15 MON 200 NIL SVT NIL 2.20 N 1.89 N 1.90 N NORMAL 
44 40 F D 12 MON 200 NIL DCMP NIL 2.67 N 1.11 N 2.18 N NORMAL 
45 35 F D 15 MON 200 NIL AF NIL 1.79 N 1.89 N 0.78 N NORMAL 
46 55 F D 15 MON 300 NIL SVT LETHARGY 0.70 D 0.00 D 24.49 I HYPO-CLI 
47 22 F D 24 MON 200 NIL SVT NIL 3.22 N 1.33 N 3.03 N NORMAL 
48 19 F D 15 MON  200 NIL SVT NIL 1.70 N 1.78 N 3.43 N NORMAL 
49 32 F D 15 MON 200 NIL SVT NIL 1.43 N 0.90 N 3.87 N NORMAL 
50 24 F I 12 MON 200 NIL SVT NIL 2.98 N 1.01 N 2.53 N NORMAL 
51 27 F I 24 MON 200 NIL SVT NIL 3.13 N 0.91 N 3.13 N NORMAL 
52 28 F D 12 MON 400 NIL SVT NIL 1.50 N 6.90 I 0.02 D THYROTOXICOSIS 
53 32 F D 18 MON 200 NIL WPW NIL 2.20 N 1.22 N 1.42 N NORMAL 
54 34 F D 12 MON 200 NIL AF NIL 3.10 N 0.98 N 0.90 N NORMAL 
55 19 F I 18 MON 200 NIL AF NIL 2.27 N 1.45 N 4.20 N NORMAL 
56 29 F D 12 MON 300 NIL SVT NIL 1.90 N 9.20 I 0.09 D SUBCLINI THYROTOX 
57 19 F D 18 MON 200 NIL WPW NIL 3.12 N 0.99 N 1.68 N NORMAL 
58 60 M I 12 MON 300 DM DCMP NIL 4.00 N 1.20 N 11.35 I HYPO-SUB 
59 85 M I 12 MON 200 DM DCMP NIL 2.21 N 1.11 N 3.95 N NORMAL 
60 49 M D 8 MON 200 DM WPW NIL 1.97 N 1.83 N 1.49 N NORMAL 
61 30 M D 15 MON 200 NIL WPW NIL 1.84 N 1.76 N 1.78 N NORMAL 
62 78 M D 24 MON 400 DM,HT DCMP WT LOSS 20.43 I 6.70 I 0.01 D THYROTOXICOSIS 
63 18 M I 18  MON 200 NIL SVT NIL 1.89 N 1.78 N 3.60 N NORMAL 
64 46 M D 18 MON 200 HT VT NIL 1.90 N 1.10 N 4.61 I NORMAL 
65 88 M D 18 MON 200 HT VT NIL 3.01 N 0.85 N 4.14 N NORMAL 
66 40 M I 12 MON 200 HT SVT NIL 2.06 N 0.92 N 1.01 N NORMAL 
67 49 M D 24 MON 200 HT VT NIL 2.97 N 0.88 N 2.46 N NORMAL 
68 48 M D 12 MON 300 DM DCMP NIL 1.80 N 7.30 I 0.04 D SUBCLINI THYROTOX 
69 80 M D 12 MON 200 DM,HT DCMP NIL 1.40 N 1.20 N 1.87 N NORMAL 
70 37 M I 15 MON 200 NIL AF NIL 1.60 N 0.93 N 3.07 N NORMAL 
71 41 M I 24 MON 200 NIL VT NIL 3.97 N 0.82 N 1.78 N NORMAL 
72 46 M I 12 MON 200 DM DCMP NIL 2.10 N 1.92 N 1.89 N NORMAL 
73 70 M I 24 MON 200 HT DCMP NIL 4.28 N 1.45 N 1.98 N NORMAL 
74 19 F I 20 MON 200 NIL DCMP NIL 2.26 N 2.00 N 2.15 N NORMAL 
75 56 M D 12 MON 200 NIL VT NIL 3.13 N 0.90 N 1.79 N NORMAL 
76 34 M D 12 MON 200 NIL SVT NIL 1.96 N 0.83 N 1.44 N NORMAL 
77 46 F D 24 MON 300 DM SVT WT LOSS 1.80 N 8.35 I 0.02 D THYROTOXICOSIS 
78 19 F D 12 MON 300 NIL SVT NIL 4.10 N 1.99 N 7.03 I HYPO-SUB 
79 21 F D 15 MON 200 NIL AF NIL 2.89 N 1.32 N 1.22 N NORMAL 
80 18 F I 18 MON 200 NIL AF NIL 1.94 N 1.99 N 1.39 N NORMAL 
81 18 F D 12 MON 300 NIL SVT palpitation 8.32 I 6.90 I 0.01 D THYROTOXICOSIS 
82 18 F D 15 MON 300 NIL SVT NIL 2.87 I 2.10 N 8.89 I HYPO-SUB 
83 20 F I 15 MON 200 NIL SVT NIL 1.77 N 0.92 N 0.40 N NORMAL 
84 62 M I 18 MON 200 DM,HT DCMP NIL 3.56 N 1.45 N 3.83 N NORMAL 
85 18 M D 18 MON 300 NIL SVT NIL 1.70 N 9.30 I 0.02 D HYPER 
86 48 M I 16 MON 200 HT DCMP NIL 3.12 N 1.34 N 1.45 N NORMAL 
87 57 M I 6 MON 200 HT VT NIL 1.87 N 2.23 N 2.82 N NORMAL 
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88 67 M I 24 MON 200 HT DCMP NIL 3.84 N 2.10 N 1.74 N NORMAL 
89 32 M D 18 MON 300 NIL SVT NIL 2.70 N 10.40 I 0.05 D SUBCLINI THYROTOX 
90 58 M I 12 MON 200 DM,HT VT NIL 1.52 N 1.94 N 2.65 N NORMAL 
91 61 M D 12 MON 200 DM,HT VT NIL 2.67 N 1.11 N 3.42 N NORMAL 
92 60 F D 18 MON 300 NIL DCMP NIL 4.15 N 1.89 N 7.65 I HYPO-SUB 
93 25 F I 18 MON 200 NIL AF NIL 1.93 N 0.84 N 0.74 N NORMAL 
94 66 F I 18 MON 200 HT VT NIL 3.34 N 1.22 N 4.24 N NORMAL 
95 45 F D 12 MON 300 DM DCMP NIL 3.80 N 9.43 I 0.07 D SUBCLINI THYROTOX 
96 60 F I 24 MON 200 NIL VT NIL 1.63 N 1.21 N 0.89 N NORMAL 
97 38 F D 24 MON 200 NIL SVT NIL 1.89 N 0.91 N 4.24 N NORMAL 
98 20 F I 12 MON 200 NIL AF NIL 1.64 N 1.82 N 4.03 N NORMAL 
99 60 F D 15 MON  300 DM,HT AF LETHARGY 0.98 D 0.00 D 21.36 I HYPO-CLI 
100 45 F D 12 MON 200 DM AF NIL 2.50 N 1.80 N 3.90 N NORMAL 
101 35 F D 18 MON 300 NIL SVT NIL 2.60 N 9.60 I 0.09 D SUBCLINI THYROTOX 
102 87 F D 15 MON 200 DM VT NIL 3.17 N 1.34 N 1.65  N NORMAL 
103 63 F I 15 MON 200 DM DCMP NIL 1.78 N 1.90 N 1.56 N NORMAL 
104 50 F D 12 MON 200 HT VT NIL 3.34 N 0.97 N 3.24 N NORMAL 
105 53 F D 12 MON 300 DM AF NIL 3.30 N 2.10 N 6.29 I HYPO-SUB 
106 50 F I 14 MON 200 HT   NIL 2.09 N 1.02 N 3.89  N NORMAL 
107 50 M I 12 MON 200 NIL SVT NIL 2.10 N 1.78 N 3.50 N NORMAL 
108 50 F I 15 MON 300 NIL AF NIL 1.42 N 1.79 N 15.75 I HYPO-SUB 
109 43 M D 24 MON 200 DM VT NIL 3.28 N 0.99 N 3.00 N NORMAL 
110 45 F I 12 MON 200 HT AF NIL 3.24 N 1.12 N 1.06 N NORMAL 
111 38 M I 14 MON 200 NIL VT NIL 2.25 N 1.91 N 1.14 N NORMAL 
112 30 M I 6 MON 200 NIL SVT NIL 3.66 N 1.11 N 1.50 N NORMAL 
113 28 M D 12 MON 200 NIL SVT NIL 1.30 N 1.79 N 1.90 N NORMAL 
114 65 M D 12 MON 200 DM DCMP NIL 2.48 N 1.87 N 4.56 N NORMAL 
115 72 M D 14 MON 200 DM,HT DCMP NIL 3.92 N 1.55 N 2.94 N NORMAL 
116 28 M D 12 MON 200 NIL SVT NIL 2.89 N 1.23 N 2.47 N NORMAL 
117 65 M I 12 MON 200 DM DCMP NIL 1.67 N 1.86 N 2.30 N NORMAL 
118 72 M I 14 MON 200 DM,HT DCMP NIL 1.69 N 1.89 N 3.40 N NORMAL 
119 45 M I 10 MON   200 NIL SVT NIL 3.87 N 0.93 N 2.19 N NORMAL 
120 45 M D 14 MON 200 NIL AF NIL 2.04 N 1.90 N 2.31 N NORMAL 
121 65 M I 12 MON 200 DM SVT NIL 1.57 N 1.79 N 4.21 N NORMAL 
122 66 M D 18 MON 200 DM,HT DCMP NIL 2.73 N 0.83 N 2.53 N NORMAL 
123 24 M I 12 MON 200 NIL SVT NIL 3.08 N 1.11 N 1.16 N NORMAL 
124 28 M D 12 MON 200 NIL SVT NIL 1.76 N 8.20 I 0.04 D SUBCLINI THYROTOX 
125 45 M D 24 MON 200 NIL AF NIL 1.67 N 2.10 N 4.21 N NORMAL 
126 62 M I 18 MON 200 HT DCMP NIL 2.24 N 1.99 N 3.83 N NORMAL 
127 18 M I 18 MON 300 NIL SVT NIL 3.33 N 1.23 N 2.15 N NORMAL 
128 48 M D 16 MON 300 NIL SVT DYSPNOEA 2.60 N 9.20 I 0.08 D SUBCLINI THYROTOX 
129 57 M I 6 MON 200 DM DCMP NIL 1.67 N 1.11 N 2.82 N NORMAL 
130 67 M I 24 MON 200 DM SVT NIL 3.85 N 2.01 N 1.74 N NORMAL 
131 32 M I 18 MON 200 NIL AF NIL 1.56 N 2.10 N 3.86 N NORMAL 
132 58 M I 12 MON 200 DM SVT NIL 1.98 N 1.23 N 2.65 N NORMAL 
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133 61 M D 12 MON 200 DM DCMP NIL 2.67 N 1.22 N 3.42 N NORMAL 
134 60 F D 18 MON 300 DM DCMP NIL 3.90 N 5.30 I 0.20 D SUBCLINI THYROTOX 
135 25 F I 18 MON 200 NIL SVT NIL 3.39 N 1.45 N 0.74 N NORMAL 
136 66 F I 18 MON 200 DM DCMP NIL 3.12 N 0.89 N 3.24 N NORMAL 
137 45 F D 12 MON 300 NIL DCMP NIL 1.83 N 1.05 N 0.74 N NORMAL 
138 60 F I 24 MON 200 DM DCMP NIL 2.15 N 1.98 N 0.89 N NORMAL 
139 38 F D 24 MON 200 NIL SVT NIL 2.74 N 0.88 N 4.24 N NORMAL 
140 20 F I 12 MON 200 NIL SVT NIL 4.24 N 0.91 N 4.35 N NORMAL 
141 60 F D 15 MON  300 DM DCMP DYSPNOEA 6.20 N 14.11 I 0.02 D THYROTOXICOSIS 
142 32 F D 12 MON 200 NIL AF NIL 2.80 N 1.77 N 1.91 N NORMAL 
143 39 F D 15 MON 200 NIL DCMP NIL 3.73 N 0.88 N 1.21 N NORMAL 
144 40 F D 12 MON 200 HT DCMP NIL 3.99 N 0.91 N 2.18 N NORMAL 
145 35 F D 15 MON 300 NIL SVT NIL 2.70 N 7.60 I 0.07 D SUBCLINI THYROTOX 
146 55 F D 15 MON 200 HT DCMP NIL 1.67 N 1.13 N 4.10 N NORMAL 
147 22 F D 24 MON 200 NIL SVT NIL 3.22 N 1.12 N 3.03 N NORMAL 
148 19 F I 15 MON  200 NIL SVT NIL 1.98 N 1.14 N 2.07 N NORMAL 
149 23 F D 15 MON 200 NIL AF NIL 1.61 N 0.81 N 3.87 N NORMAL 
150 34 F I 12 MON 200 NIL AF NIL 3.30 N 1.67 N 2.53 N NORMAL 
151 27 F I 24 MON 200 NIL AF NIL 2.71 N 0.99 N 3.10 N NORMAL 
152 22 F D 12 MON 400 NIL SVT NIL 1.50 N 7.30 I 0.01 D THYROTOXICOSIS 
153 30 F D 18 MON 200 NIL AF NIL 2.04 N 1.99 N 1.42 N NORMAL 
154 19 F D 12 MON 200 NIL AF NIL 2.12 N 1.14 N 0.90 N NORMAL 
155 19 F I 18 MON 400 NIL SVT NIL 1.90 N 2.00 N 5.20 I HYPO-SUB 
156 21 F I 12 MON 200 NIL SVT NIL 3.47 N 1.03 N 0.91 N NORMAL 
157 29 F I 18 MON 200 NIL SVT NIL 1.90 N 1.87 N 2.40 N NORMAL 
158 60 M I 12 MON 300 NIL AF NIL 3.98 N 2.10 N 11.35 I HYPO-SUB 
159 85 M I 12 MON 200 DM,HT DCMP NIL 2.21 N 1.99 N 3.95 N NORMAL 
160 49 M D 8 MON 200 DM AF NIL 3.60 N 1.09 N 1.49 N NORMAL 
161 30 M I 15 MON 200 NIL AF NIL 3.84 N 0.87 N 0.55 N NORMAL 
162 78 M I 24 MON 400 DM DCMP DYSPNOEA 20.43 I 2.30 I 0.01 D THYROTOXICOSIS 
163 18 M D 18  MON 200 NIL SVT NIL 1.89 N 2.01 N 1.59 N NORMAL 
164 46 M D 18 MON 200 DM DCMP NIL 3.98 N 1.99 N 4.31 I NORMAL 
165 88 M D 18 MON 400 DM,HT SVT NIL 3.71 N 0.85 N 4.14 N NORMAL 
166 40 M I 12 MON 200 DM SVT NIL 2.06 N 0.94 N 1.01 N NORMAL 
167 49 M D 24 MON 400 NIL SVT WT LOSS 12.97 I 1.90 N 0.02 D THYROTOXICOSIS 
168 48 M I 12 MON 200 DM SVT NIL 3.20 N 0.93 N 0.48 N NORMAL 
169 80 M D 12 MON 200 HT DCMP NIL 2.32 N 1.99 N 1.87 N NORMAL 
170 37 M I 15 MON 200 HT SVT NIL 2.63 N 1.04 N 3.07 N NORMAL 
171 41 M I 24 MON 400 NIL SVT DYSPNOEA 13.97 I 2.00 N 0.01 D THYROTOXICOSIS 
172 46 M I 12 MON 200 DM AF NIL 3.88 N 0.86 N 1.31 N NORMAL 
173 70 M D 24 MON 400 DM,HT DCMP NIL 4.25 N 1.25 N 6.14 I HYPO-SUB 
174 19 F I 6 MON 200 NIL SVT NIL 2.10 N 1.89 N 1.98 N NORMAL 
175 56 M D 12 MON 200 HT DCMP NIL 3.66 N 1.98 N 1.79 N NORMAL 
176 34 M D 12 MON 200 NIL AF NIL 3.96 N 1.21 N 1.44 N NORMAL 
177 46 F D 24 MON 300 NIL AF NIL 4.20 N 0.92 N 1.64 N NORMAL 
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178 19 F D 12 MON 300 NIL SVT NIL 3.99 N 1.90 N 7.03 I HYPO-SUB 
179 21 F D 15 MON 200 NIL SVT NIL 2.73 N 1.09 N 1.22 N NORMAL 
180 18 F I 18 MON 200 NIL SVT NIL 1.92 N 0.87 N 1.39 N NORMAL 
181 23 F D 12 MON 300 NIL SVT NIL 3.32 N 1.01 N 1.68 N NORMAL 
182 25 F D 15 MON 200 NIL SVT NIL 4.05 N 1.80 N 3.50 N NORMAL 
183 50 M I 12 MON 300 NIL DCMP NIL 3.40 N 1.84 N 3.90 N NORMAL 
184 50 F I 15 MON 200 DM AF NIL 1.42 N 1.70 N 4.30 N NORMAL 
185 43 M D 24 MON 400 DM DCMP DYSPNOEA 13.28 I 2.20 I 0.01 D THYROTOXICOSIS 
186 45 F I 12 MON 200 HT DCMP NIL 3.14 N 1.12 N 1.06 N NORMAL 
187 38 M I 14 MON 300 NIL AF NIL 4.25 N 1.91 N 1.14 N NORMAL 
188 30 M I 6 MON 200 NIL SVT NIL 3.66 N 0.91 N 1.50 N NORMAL 
189 28 M D 12 MON 200 NIL SVT NIL 4.00 N 2.00 N 3.89 N NORMAL 
190 65 M D 12 MON 200 NIL DCMP NIL 3.48 N 1.98 N 3.46 N NORMAL 
191 72 M D 14 MON 200 HT DCMP NIL 2.99 N 1.07 N 2.94 N NORMAL 
192 45 M I 10 MON   300 HT SVT NIL 2.04 N 0.83 N 2.19 N NORMAL 
193 45 M D 14 MON 300 NIL DCMP palpitation 12.04 I 2.90 I 0.02 D THYROTOXICOSIS 
194 65 M I 12 MON 200 NIL AF NIL 2.10 N 1.98 N 3.30 N NORMAL 
195 66 M D 18 MON 200 DM DCMP NIL 2.71 N 1.81 N 2.53 N NORMAL 
196 24 M I 12 MON 200 NIL AF NIL 3.08 N 1.19 N 1.16 N NORMAL 
197 28 M D 12 MON 200 NIL AF NIL 1.76 N 1.99 N 3.24 N NORMAL 
198 45 M D 24 MON 200 DM DCMP NIL 3.79 N 1.24 N 4.21 N NORMAL 
199 62 M I 18 MON 200 DM DCMP NIL 2.24 N 1.11 N 3.83 N NORMAL 
200 19 F D 12 MON 300 NIL SVT WT LOSS 8.70 I 1.80 N 0.02 D THYROTOXICOSIS 
 
